FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2057282229> ?p ?o ?g. }

• W2057282229 endingPage "8" @default.
• W2057282229 startingPage "1" @default.
• W2057282229 abstract "Background . Efficacy of adding bevacizumab in first-line chemotherapy of metastatic colorectal cancer (mCRC) has been controversial. The aim of this study is to gather current data to analyze efficacy of adding bevacizumab to the most used combination first-line chemotherapy in mCRC, based on the 2012 meta-analysis reported by Macedo et al. Methods . Medline, EMBASE and Cochrane library, meeting presentations and abstracts were searched. Eligible studies were randomized controlled trials (RCTs) which evaluated first-line chemotherapy with or without bevacizumab in mCRC. The extracting data were included and examined in the meta-analysis according to the type of chemotherapy regimen. Results . Seven trials, totaling 3436 patients, were analyzed. Compared with first-line chemothery alone, the adding of bevacizumab did not show clinical benefit for OS both in first-line therapy and the most used combination chemotherapy (HR = 0.89; 95% CI = 0.78–1.02;<mml:math xmlns:mml=http://www.w3.org/1998/Math/MathML id=M1><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>0.08</mml:mn></mml:math>; HR = 0.93; 95% CI = 0.83–1.05;<mml:math xmlns:mml=http://www.w3.org/1998/Math/MathML id=M2><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>0.24</mml:mn></mml:math>). In contrast with OS, the addition of bevacizumab resulted in significant improvement for PFS (HR = 0.68; 95% CI = 0.59–0.78;<mml:math xmlns:mml=http://www.w3.org/1998/Math/MathML id=M3><mml:mi>P</mml:mi><mml:mo><</mml:mo><mml:mn>0.00001</mml:mn></mml:math>). Moreover, it also demonstrated statistical benefit for PFS in the most used combination first-line chemotherapy (HR = 0.84; 95% CI = 0.75–0.94;<mml:math xmlns:mml=http://www.w3.org/1998/Math/MathML id=M4><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>0.002</mml:mn></mml:math>). And the subgroup analysis indicated only capacitabine-based regimens were beneficial. Conclusions . This meta-analysis shows that the addition of bevacizumab to FOLFOX/FOLFIRI/XELOX regimens might not be beneficial in terms of OS. Benefit has been seen when PFS has been taken into account. In subgroup analysis, benefit adding bevacizumab has been seen when capecitabine-based regimens are used. Further studies are warranted to explore the combination with bevacizumab." @default.
• W2057282229 created "2016-06-24" @default.
• W2057282229 creator A5002124900 @default.
• W2057282229 creator A5032277221 @default.
• W2057282229 creator A5074499822 @default.
• W2057282229 creator A5074835551 @default.
• W2057282229 creator A5075582658 @default.
• W2057282229 creator A5078073042 @default.
• W2057282229 creator A5078767303 @default.
• W2057282229 date "2014-01-01" @default.
• W2057282229 modified "2023-10-16" @default.
• W2057282229 title "Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer: Evidence from Seven Randomized Clinical Trials" @default.
• W2057282229 cites W1981679880 @default.
• W2057282229 cites W2008009461 @default.
• W2057282229 cites W2012852444 @default.
• W2057282229 cites W2044792687 @default.
• W2057282229 cites W2046000826 @default.
• W2057282229 cites W2048067273 @default.
• W2057282229 cites W2077421021 @default.
• W2057282229 cites W2085705101 @default.
• W2057282229 cites W2096651590 @default.
• W2057282229 cites W2112727687 @default.
• W2057282229 cites W2113919377 @default.
• W2057282229 cites W2122152991 @default.
• W2057282229 cites W2128403792 @default.
• W2057282229 cites W2133399075 @default.
• W2057282229 cites W2143743735 @default.
• W2057282229 cites W2146350639 @default.
• W2057282229 cites W2156575195 @default.
• W2057282229 cites W2157769714 @default.
• W2057282229 cites W2160373161 @default.
• W2057282229 cites W2166573361 @default.
• W2057282229 doi "https://doi.org/10.1155/2014/594930" @default.
• W2057282229 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4058184" @default.
• W2057282229 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24971091" @default.
• W2057282229 hasPublicationYear "2014" @default.
• W2057282229 type Work @default.
• W2057282229 sameAs 2057282229 @default.
• W2057282229 citedByCount "16" @default.
• W2057282229 countsByYear W20572822292016 @default.
• W2057282229 countsByYear W20572822292017 @default.
• W2057282229 countsByYear W20572822292018 @default.
• W2057282229 countsByYear W20572822292019 @default.
• W2057282229 countsByYear W20572822292021 @default.
• W2057282229 countsByYear W20572822292022 @default.
• W2057282229 countsByYear W20572822292023 @default.
• W2057282229 crossrefType "journal-article" @default.
• W2057282229 hasAuthorship W2057282229A5002124900 @default.
• W2057282229 hasAuthorship W2057282229A5032277221 @default.
• W2057282229 hasAuthorship W2057282229A5074499822 @default.
• W2057282229 hasAuthorship W2057282229A5074835551 @default.
• W2057282229 hasAuthorship W2057282229A5075582658 @default.
• W2057282229 hasAuthorship W2057282229A5078073042 @default.
• W2057282229 hasAuthorship W2057282229A5078767303 @default.
• W2057282229 hasBestOaLocation W20572822291 @default.
• W2057282229 hasConcept C11413529 @default.
• W2057282229 hasConcept C121608353 @default.
• W2057282229 hasConcept C126322002 @default.
• W2057282229 hasConcept C143998085 @default.
• W2057282229 hasConcept C168563851 @default.
• W2057282229 hasConcept C2776478404 @default.
• W2057282229 hasConcept C2776694085 @default.
• W2057282229 hasConcept C2777802072 @default.
• W2057282229 hasConcept C2780962732 @default.
• W2057282229 hasConcept C41008148 @default.
• W2057282229 hasConcept C526805850 @default.
• W2057282229 hasConcept C71924100 @default.
• W2057282229 hasConceptScore W2057282229C11413529 @default.
• W2057282229 hasConceptScore W2057282229C121608353 @default.
• W2057282229 hasConceptScore W2057282229C126322002 @default.
• W2057282229 hasConceptScore W2057282229C143998085 @default.
• W2057282229 hasConceptScore W2057282229C168563851 @default.
• W2057282229 hasConceptScore W2057282229C2776478404 @default.
• W2057282229 hasConceptScore W2057282229C2776694085 @default.
• W2057282229 hasConceptScore W2057282229C2777802072 @default.
• W2057282229 hasConceptScore W2057282229C2780962732 @default.
• W2057282229 hasConceptScore W2057282229C41008148 @default.
• W2057282229 hasConceptScore W2057282229C526805850 @default.
• W2057282229 hasConceptScore W2057282229C71924100 @default.
• W2057282229 hasLocation W20572822291 @default.
• W2057282229 hasLocation W20572822292 @default.
• W2057282229 hasLocation W20572822293 @default.
• W2057282229 hasLocation W20572822294 @default.
• W2057282229 hasOpenAccess W2057282229 @default.
• W2057282229 hasPrimaryLocation W20572822291 @default.
• W2057282229 hasRelatedWork W1997133872 @default.
• W2057282229 hasRelatedWork W2050348440 @default.
• W2057282229 hasRelatedWork W2051540233 @default.
• W2057282229 hasRelatedWork W2098707609 @default.
• W2057282229 hasRelatedWork W2145753255 @default.
• W2057282229 hasRelatedWork W2316610093 @default.
• W2057282229 hasRelatedWork W2340695374 @default.
• W2057282229 hasRelatedWork W2465617904 @default.
• W2057282229 hasRelatedWork W2545945608 @default.
• W2057282229 hasRelatedWork W1967062665 @default.
• W2057282229 hasVolume "2014" @default.
• W2057282229 isParatext "false" @default.
• W2057282229 isRetracted "false" @default.

• next